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Cognitive impairment, including impaired social cognition, is largely responsible for the deterioration
in social life suffered by patients with psychiatric disorders, such as schizophrenia and major
depressive disorder (MDD). Brexpiprazole (7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quino-
lin-2(1H)-one), a novel serotonin–dopamine activity modulator, was developed to offer efﬁcacious and
tolerable therapy for different psychiatric disorders, including schizophrenia and adjunctive treatment
of MDD. In this study, we investigated whether brexpiprazole could improve social recognition deﬁcits
(one of social cognition deﬁcits) in mice, after administration of the N-methyl-D-aspartate (NMDA)
receptor antagonist MK-801 (dizocilpine). Dosing with dizocilpine (0.1 mg/kg) induced signiﬁcant
impairment of social recognition in mice. Brexpiprazole (0.01, 0.03, 0.1 mg/kg, p.o.) signiﬁcantly
ameliorated dizocilpine-induced social recognition deﬁcits, without sedation or a reduction of
exploratory behavior. In addition, brexpiprazole alone had no effect on social recognition in untreated
control mice. By contrast, neither risperidone (0.03 mg/kg, p.o.) nor olanzapine (0.03 mg/kg, p.o.)
altered dizocilpine-induced social recognition deﬁcits. Finally, the effect of brexpiprazole on
dizocilpine-induced social recognition deﬁcits was antagonized by WAY-100,635, a selective serotonin
5-HT1A antagonist. These results suggest that brexpiprazole could improve dizocilpine-induced social
recognition deﬁcits via 5-HT1A receptor activation in mice. Therefore, brexpiprazole may confer a
beneﬁcial effect on social cognition deﬁcits in patients with psychiatric disorders.
& 2015 Elsevier B.V. and ECNP. All rights reserved.o.2014.12.014
CNP. All rights reserved.
ical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba 260-8670,
1 43 226 2561.
.chiba-u.jp (K. Hashimoto).
357Improvement of dizocilpine-induced social recognition deﬁcits in mice by brexpiprazole1. Introduction
Cognitive impairment describes a diverse range of deﬁcits, seen
in psychiatric disorders. Of these, impaired social cognition gre-
atly hampers everyday life, resulting in poor work productivity
or underemployment of patients with schizophrenia and major
depressive disorder (MDD) (Tandberg et al., 2011; Tse et al.,
2013; Horan et al., 2012; Lo and Siu, in press). It is generally
accepted that reducing social cognitive dysfunction is an impor-
tant factor in assisting psychiatric patients to make healthy
adjustments in their social lives (Tandberg et al., 2011; Tse
et al., 2013; Horan et al., 2012; Trapp et al., 2013). Current
reports suggest that training of social cognition may help to
improve functional outcome in patients with schizophrenia
(Henderson, 2013). To complement this, the development of
novel drugs to improve social cognition deﬁcits in patients with
schizophrenia is also imperative.
Social recognition testing is designed to measure the pro-
pensity of a mouse to make contact with a novel rather than
familiar mouse. This testing therefore represents a cognitive
model that reﬂects innate ability to communicate with others
(Moy et al., 2004; van der Kooij and Sandi, 2012). Social
recognition test in rodents is also one of the assays for
evaluating social cognition in humans (Millan and Bales,
2013). Based on the N-methyl-D-aspartate (NMDA) hypofunction
hypothesis of schizophrenia (Hashimoto, 2006, 2014; Hashimoto
et al., 2013), the NMDA receptor antagonist, (+)-MK-801
(dizocilpine), is widely used to induce schi-
zophrenia-like behavioral abnormalities, including positive and
negative symptoms and cognitive deﬁcits in rodents (Hashimoto
et al., 2009; Karasawa et al., 2008; Rajagopal et al., 2014;
Meltzer et al., 2011; Okamura et al., 2004; Rogoz, 2013; Zhang
et al., 2007). Furthermore, dizocilpine also impairs social
interaction and social recognition (Maehara et al., 2011; Oh
et al., 2013; Hikichi et al., 2013).
Brexpiprazole, 7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-
yl]butoxy} quinolin-2(1H)-one, is a novel serotonin–dopamine
activity modulator with high afﬁnity for serotonin, dopamine
and noradrenaline receptors (Maeda et al., 2014a). It is a
partial agonist at serotonin 5-HT1A and dopamine D2 recep-
tors, with a relatively equal potency, and an antagonist at 5-
HT2A receptors and adrenergic α1B/2C receptors. Brexpipra-
zole is currently under clinical evaluation and expected to
show efﬁcacy and tolerability when used as therapy for
different psychiatric disorders, including schizophrenia and
adjunctive treatment for MDD. Very recently, brexpiprazole
was shown to improve the NMDA receptor antagonist
phencyclidine-induced cognitive deﬁcits in the novel object
recognition test in rodents (Maeda et al., 2014b; Yoshimi
et al., 2014). To date, the effect of brexpiprazole on social
recognition has not been investigated. In this study, we
evaluated the effects of brexpiprazole on dizocilpine-
induced social recognition deﬁcits in mice.2. Experimental procedures
2.1. Animals
Male C57BL/6NCrSlc mice (Japan SLC Inc., Shizuoka, Japan) aged
between 4 and 5 weeks old were selected as stranger mice, while
animals between 8 and 10 weeks old were used for this study. All micewere housed in groups of ﬁve per cage, in a room maintained at
2372 1C and 60710% humidity, with a 12/12 h light/dark cycle (lights
on at 7:00 a.m.). The mice were given free access to food and water.
Animal care and use were conducted in accordance with the Institu-
tional Guidelines for Animal Care and Use (Otsuka Pharmaceutical Co.,
Ltd., Tokushima, Japan).
2.2. Drugs
(+)-MK-801 hydrogen maleate (dizocilpine) was purchased from
Sigma-Aldrich Co., Ltd. (Tokyo, Japan). Brexpiprazole, risperidone,
olanzapine and WAY-100,635 were synthesized at Otsuka Pharma-
ceutical Co., Ltd. (Tokyo, Japan). Dizocilpine was dissolved in saline
and administered intraperitoneally (i.p.) at 10 ml/kg, twice daily,
on the day before and 30 min prior to sociability testing. Brexpi-
prazole, risperidone, olanzapine and WAY-100,635 were dissolved in
5% (w/v) gum Arabic and administered orally (p.o.), at 10 ml/kg,
1 h prior to sociability testing. The doses of dizocilpine (0.1 mg/kg)
and WAY-100,635 (1.0 mg/kg) were selected from previously pub-
lished reports in mice (Hagiwara et al., 2008; Hashimoto et al.,
2009; Takatsu et al., 2011; Yoshimi et al., 2014; Zhang et al., 2007).
The doses of antipsychotic drugs were selected based on doses that
did not impact locomotion (data not shown).
2.3. Apparatus
The test apparatus consisted of a rectangular, three-chambered box,
and a lid with an attached infrared video camera (O'Hara & Co., Ltd.,
Tokyo, Japan). The apparatus was 610W 400D 220H mm3, and the
dividing walls were made from clear Plexiglass, with small square
openings (3 5 cm2) allowing access into each chamber. The stranger
mouse was enclosed in a small, round wire cage (diameter, 10 cm;
height, 12 cm), allowing olfactory, visual, auditory, and tactile
contact, but no deep contact. Using a CCD camera, measures were
taken of the amount of time spent around the wire cage. The total
distance traveled was calculated based on traced mice movement
and presented as the locomotor activity in this study. All data were
computerized. Activity was monitored and analyzed using applica-
tions based on the public domain NIH Image or Image J program
(developed by Wayne Rasband at the U.S. National Institute of
Mental Health and available on the Internet at http://rsb.info.nih.
gov/nih-image/) (O'Hara & Co., Ltd., Tokyo, Japan).
2.4. Behavioral procedures
The measurement of sociability and social recognition was performed
using the same procedure described in previous reports (Moy et al.,
2007; Nakatani et al., 2009; Matsuo et al., 2009; Riedel et al., 2009). In
this study, we focused on a narrowly deﬁned set of parameters.
2.4.1. Habituation
Mice were randomly assigned to groups. Mice were ﬁrst placed in
the middle compartment of the apparatus and allowed to explore
freely for 6 min. All other compartments were empty during this
habituation period.
2.4.2. Sociability test
An unfamiliar male (stranger) that had no prior contact with the
mouse was placed in one of the side chambers. After the habitua-
tion period, the unfamiliar male juvenile mouse (stranger 1) was
placed inside the round wire cage, in one of the side compartments
(randomly selected and counterbalanced for each group). The
opposite compartment was empty. The mice were able to freely
explore all three compartments of the apparatus for 6 min. The
time spent around cages (stranger 1 or empty) was calculated as
direct contact.
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After sociability testing, a novel unfamiliar juvenile mouse (stran-
ger 2) was placed inside a new round wire cage and introduced to
the ‘empty compartment’ of the apparatus. Mice were conﬁned to
the central compartment and were able to explore freely in all
compartments for 10 min.
The recognition index (RI) was calculated using parameters measured
during social recognition sessions and was deﬁned as the quotient of the
time the mouse spent around the novel juvenile (stranger 2) divided by
the sum of the time spent around the familiar (stranger 1) and novel
(stranger 2) juvenile mice.2.5. Statistical analyses
All statistical analyses were performed using Prism 5 (GraphPad Software
Inc., La Jolla, USA). Data are presented as mean7standard error of the
mean (S.E.M.). To determine the effects of drug treatment, one-way
ANOVA, followed by the post-hoc Bonferroni test (for RI and total
distance) or a two-tailed paired t-test (for RI and time spent around
cage), was used. p Values of less than 0.05 were considered statistically
signiﬁcant.Figure 1 Effects of brexpiprazole on dizocilpine-induced social recogn
was administered twice daily on the day before and 30 min prior to socia
(5% (w/v) gum Arabic, p.o.) was administrated 1 h prior to sociability te
(RI), that is, the quotient of time the subject mouse spent around the no
around the familiar (stranger 1) and novel juvenile (stranger 2) mice d
each stranger during the social recognition sessions and, (C) exploratory
E.M (n=11–15). *po0.05, **po0.01, ***po0.001 compared with dizocilp
Bonferroni test). **po0.01, ***po0.001 compared with stranger 1 mice
p.o.) or vehicle (5% (w/v) gum Arabic, p.o.) was administrated 1 h prio
duration of time spent around each stranger mouse (E), and explorato
mean7S.E.M (n=7–14). *po0.05, **po0.01, ***po0.001 compared wit3. Results
3.1. Effects of brexpiprazole on dizocilpine-
induced social recognition deﬁcits
Mice in all groups spent signiﬁcantly more time around
stranger 1, than the empty area in sociability sessions (data
not shown). A one-way ANOVA on RI in social recognition
session showed a signiﬁcant effect of treatment (F(4, 56)=5.83,
po0.001) (Figure 1A). Saline-treated control mice had a
signiﬁcant preference for spending more time with the novel
unfamiliar stranger 2, in comparison with familiar stranger 1,
in the social recognition session (Figure 1B). Treatment with
dizocilpine (0.1 mg/kg, i.p.) signiﬁcantly decreased the total
time spent around stranger 2 in social recognition sessions. A
paired t-test showed a signiﬁcant (po0.01) impairment of RI
in the dizocilpine-treated group. Mice spent the same amount
of time interacting with stranger 1 and stranger 2 mice
(Figure 1A and B). The total distance moved (exploratory
behavior), indicative of locomotor activity, was signiﬁcantly
increased by dizocilpine administration (Figure 1C).ition deﬁcits. Dizocilpine (0.1 mg/kg, i.p.) or saline (10 ml/kg, i.p.)
bility testing. Brexpiprazole (0.01, 0.03, 0.1 mg/kg, p.o.) or vehicle
sting. (A) Social recognition was measured by the recognition index
vel juvenile (stranger 2) mouse divided by the sum of the time spent
uring social recognition sessions. (B) Duration of time spent around
behavior during social recognition sessions. Values are the mean7S.
ine+vehicle group (A and C, one-way ANOVA, followed by post-hoc
(B, two-tailed paired t-test). Brexpiprazole (0.01, 0.03, 0.1 mg/kg,
r to sociability testing. The effects of brexpiprazole on the RI (D),
ry behavior (F), during social recognition sessions. Values are the
h stranger 1 (E, two-tailed paired t-test). N.S.: not signiﬁcant.
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dizocilpine-induced social recognition deﬁcits in mice. Neither
dizocilpine (0.1 mg/kg, i.p.) nor brexpiprazole (0.01, 0.03 and
0.1 mg/kg, p.o.) altered the amount of time spent around
stranger 1 mice in sociability sessions (data not shown).
However, at all three doses of brexpiprazole, mice treated
with brexpiprazole showed a signiﬁcant preference for spend-
ing more time with novel unfamiliar stranger 2 mice, com-
pared with familiar stranger 1 mice in social recognition
sessions (Figure 1B), and additionally, impaired RI was sig-
niﬁcantly restored by treatment with brexpiprazole at the
same doses used in sociability testing (Figure 1A). Further-
more, brexpiprazole (0.01, 0.03 and 0.1 mg/kg) did not
temper the increased locomotor activity induced by dizocil-
pine in social recognition sessions (Figure 1C).
3.2. Brexpiprazole alone did not affect social
recognition or exploratory behavior
We examined the effect of brexpiprazole on social recognition
in untreated control mice. Treatment with brexpiprazole
(0.01, 0.03 and 0.1 mg/kg) had no effect on the time spentFigure 2 Effect of risperidone on dizocilpine-induced social recogn
i.p.) was administered twice daily on the day before and 30 min prio
(5% (w/v) gum Arabic, p.o.) was administrated 1 h prior to sociabilit
spent around each stranger mouse (B), and exploratory behavior (C)
(n=11 or 12). *po0.05 compared with dizocilpine+vehicle group (A
N.S.: not signiﬁcant. **po0.01 compared with stranger 1 mice (B
vehicle (5% (w/v) gum Arabic, p.o.) was administrated 1 h prior to s
of time spent around each stranger mouse (E) and exploratory b
mean7S.E.M (n=7). *po0.05 compared with the vehicle-treated
***po0.001 compared with stranger 1 mice (E, two-tailed paired t-around stranger 1 mice in either sociability (data not shown)
or social recognition sessions (Figure 1D and E). Brexpiprazole
did not alter RI in social recognition sessions (Figure 1D), nor
did it have an effect on exploratory behavior during either
session (Figure 1F).
3.3. Risperidone and olanzapine had no effect on
dizocilpine-induced social recognition deﬁcits
We examined whether the atypical antipsychotic drugs, risper-
idone and olanzapine, affected dizocilpine-induced social recog-
nition deﬁcits in mice. A one-way ANOVA on RI in social reco-
gnition session showed a signiﬁcant effect of treatment (F(2,
31)=4.60, po0.05) (Figure 2A). Post-hoc analysis showed that
risperidone (0.03 mg/kg, p.o.) did not ameliorate dizocilpine-
induced social recognition deﬁcits (Figure 2A and B), and
dizocilpine-induced hyperlocomotion in the recognition sessions
(Figure 2C). When administered alone, risperidone (0.03 mg/kg,
p.o.) signiﬁcantly decreased both RI and locomotor activity in
untreated control mice (Figure 2D–F).
A one-way ANOVA on RI in social recognition session sho-
wed a signiﬁcant effect of treatment (F(2, 27)=7.72, po0.01)ition deﬁcits. Dizocilpine (0.1 mg/kg, i.p.) or saline (10 ml/kg,
r to sociability testing. Risperidone (0.03 mg/kg, p.o.) or vehicle
y testing. The effects of risperidone on RI (A), duration of time
during social recognition sessions. Values are the mean7S.E.M
and C, one-way ANOVA, followed by post-hoc Bonferroni test).
, two-tailed paired t-test). Risperidone (0.03 mg/kg, p.o.) or
ociability testing. The effects of risperidone on RI (D), duration
ehavior (F) during social recognition sessions. Values are the
control group (D and F, two-tailed paired t-test). *po0.05,
test).
Figure 3 Effect of olanzapine on dizocilpine-induced social recognition deﬁcits. Dizocilpine (0.1 mg/kg, i.p.) or saline (10 ml/kg,
i.p.) administered twice daily on the day before and 30 min prior to sociability testing. Olanzapine (0.03 mg/kg, p.o.) or vehicle (5%
(w/v) gum Arabic, p.o.) was administrated 1 h prior to sociability testing. The effects of olanzapine on RI (A), duration of time spent
around each stranger mouse (B) and exploratory behavior (C) during social recognition sessions. Values are the mean7S.E.M (n=10).
**po0.01, ***po0.001 compared with vehicle-treated control group for (A) and (C) (one-way ANOVA, followed by post-hoc
Bonferroni test). ***po0.001 compared with stranger 1 mice for (B) (two-tailed paired t-test). Olanzapine (0.03 mg/kg, p.o.) or
vehicle (5% (w/v) gum Arabic, p.o.) was administrated 1 h prior to sociability testing. The effects of olanzapine on RI (D), duration of
time spent around each stranger mouse (E) and exploratory behavior (F) during social recognition sessions. Values are the mean7S.
E.M (n=7). **po0.01, ***po0.001 compared with stranger 1 mice for (E) (two-tailed paired t-test). N.S.: not signiﬁcant.
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kg, p.o.) did not affect time spent around stranger 2 mice,
nor did it reverse dizocilpine-induced impairment of the RI
(Figure 3A and B). Furthermore, olanzapine had no effect on
dizocilpine-induced hyperlocomotion in the recognition sessions
(Figure 3C). Olanzapine (0.03 mg/kg, p.o.) alone was incapable
of altering RI, the time spent around stranger 2 mice, or
exploratory behavior in untreated control mice (Figure 3D–F).
3.4. Role of the 5-HT1A receptor in
brexpiprazole's effects on dizocilpine-induced
social recognition deﬁcits
To investigate the function of serotonin 5-HT1A receptors in
the pharmacological effect of brexpiprazole on dizocilpine-
induced social recognition deﬁcits, we examined the effect
of WAY-100,635, a selective 5-HT1A receptor antagonist. A
one-way ANOVA on RI in social recognition session showed a
signiﬁcant effect of treatment (F(4, 57)=7.82, po0.0001)
(Figure 4A). Post-hoc analysis showed that WAY-100,635
(1.0 mg/kg, p.o.) signiﬁcantly antagonized the effect of
brexpiprazole on dizocilpine-induced social recognitiondeﬁcits (Figure 4A and B). Treatment with WAY-100,635
alone did not alter RI and locomotion in dizocilpine-treated
mice (Figure 4A and C). Furthermore, treatment with WAY-
100,635 alone did not affect RI, the time spent around
stranger 2 mice, or exploratory behavior in untreated
control mice (Figure 4D–F).
4. Discussion
The two major ﬁndings of this study are that the novel
serotonin–dopamine activity modulator brexpiprazole, but
not risperidone or olanzapine, improved social recognition
deﬁcits in mice after the administration of dizocilpine, and
that 5-HT1A receptors are critical to this beneﬁcial effect.
Antipsychotic drugs, such as risperidone and olanzapine, are
known to show limited efﬁcacy in cognitive impairment,
including social recognition in schizophrenia and depression
(Sergi et al., 2007; Krakowski and Czobor, 2011; Suzuki et al.,
2011; Remberk et al., 2012), despite improving various
cognitive functions in rodent disease models (Wang et al.,
2007; Gumuslu et al., 2013; Mutlu et al., 2011, 2012; Wolff
and Leander, 2003). It is of considerable clinical importance
Figure 4 Effect of a 5-HT1A antagonist on brexpiprazole's action in the dizocilpine-induced social recognition deﬁcits model.
Dizocilpine (0.1 mg/kg, i.p.) or saline (10 ml/kg, i.p.) was administered twice daily on the day before and 30 min prior to sociability
testing. Brexpiprazole (Brex: 0.03 mg/kg, p.o.), WAY-100,635 (WAY: 1 mg/kg, p.o.), or vehicle (5% (w/v) gum Arabic, p.o.) was
administrated 1 h prior to sociability testing. The effects of brexpiprazole on RI (A), duration of time spent around each stranger
mouse (B) and exploratory behavior (C) during social recognition sessions. Values are the mean7S.E.M (n=11–13). *po0.05,
***po0.001 compared with dizocilpine+vehicle group, ###po0.001 compared with the dizocilpine plus brexpiprazole-treated group
(A, one-way ANOVA, followed by post-hoc Bonferroni test). *po0.05, ***po0.001 compared with stranger 1 mice (B, two-tailed
paired t-test). N.S.: not signiﬁcant. WAY-100,635 (WAY: 1.0 mg/kg, p.o.), or vehicle (5% (w/v) gum Arabic, p.o.) was administrated
1 h prior to sociability testing. The effects of WAY-100,635 on RI (D), duration of time spent around each stranger mouse (E) and
exploratory behavior (F) during social recognition sessions were shown. Values are the mean7S.E.M (n=7). ***po0.001 compared
with stranger 1 mice (E, two-tailed paired t-test). N.S.: not signiﬁcant.
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patients with psychiatric diseases, such as schizophrenia and
MDD, because of their huge negative impact on the social
functioning of patients (Tandberg et al., 2011; Tse et al.,
2013; Horan et al., 2012). There are noted discrepancies in
antipsychotic drug effects between rodents and humans,
increasing the need for further detailed clinical studies on
the effects of brexpiprazole on social recognition in patients
with psychiatric diseases.
Social recognition testing is a paradigm capable of evaluating
social recognition, based on the propensity of an individual
mouse to spend more time with an unfamiliar mouse than with a
familiar mouse (Riedel et al., 2009; Nakatani et al., 2009). In
other cognitive tests performed in rodents, mice discriminate
objects by vision in the novel objective recognition test, by
hearing in the fear conditioning test and by odor in the social
transmission food preference test (Hashimoto et al., 2005, 2007;
Boix-Trelis et al., 2007; Amann et al., 2010). However, since
social recognition testing incorporates various factors such as
visual, auditory and olfactory function and some tactile stimuli
needed for mouse sociability, this test provides a comprehensiveevaluation of cognition in rodents, compared with other cogni-
tive tests (Nadler et al., 2004; Moy et al., 2004, 2007). There-
fore, the social recognition test in mice may represent a
translational rodent model for human social cognition, since
the model utilizes multiple aspects of mice socialization.
Here, we evaluated social recognition using an auto-
mated three-chambered apparatus system. This apparatus
is capable of measuring the time and distance a subject
mouse covers in approaching a novel mouse, thereby
evaluating the subject's motivation to interact with the
novel mouse. Furthermore, this system can also measure
exploratory behavior by producing a representative trace of
locomotor activity. This means that effects on locomotion,
such as, sedation by a drug, can be easily detected. Since
stranger mice were isolated individually in a wire cage, the
subject mouse could interact with a stranger mouse without
attack or aversive stimuli. This makes the social recognition
test in mice a potential tool for assessing the efﬁcacy of
new drugs on social recognition.
We found that the 5-HT1A antagonist, WAY-100,635, reversed
the effects of brexpiprazole on dizocilpine-induced social
N. Yoshimi et al.362recognition deﬁcits, indicating that 5-HT1A receptors are critical
to brexpiprazole's mechanism of action. A report suggests that
5-HT1A receptor agonism is related to social recognition in rats
(Millan et al., 2004). In addition, it is reported that 5-HT1A
receptors are important in the action of other antipsychotic
drugs (perospirone, aripiprazole, blonanserin), when tested in a
phencyclidine-induced cognitive deﬁcits model (Hagiwara
et al., 2008; Nagai et al., 2009; Horiguchi and Meltzer, 2012,
2013). In contrast, WAY-100,635 could alleviate cognitive
deﬁcits in monkeys after administration of dizocilpine (Harder
and Ridley, 2000), suggesting pro-cognitive effect of 5-HT1A
receptor antagonist. However, in this study, WAY-100,635 alone
had no effect in social recognition in both dizocilpine-treated
and vehicle-treated control mice. Further studies of the effects
of 5-HT1A receptor agonists and antagonists on social recogni-
tion are needed. Previously, Sumiyoshi et al. (2001a, 2001b,
2007) reported that treatment with tandospirone (or buspir-
one), 5-HT1A receptor agonists, improved cognition including
executive function and verbal learning in patients with schizo-
phrenia, indicating a key role of 5-HT1A receptor in cognition in
patients (Meltzer and Sumiyoshi, 2008; Sumiyoshi et al., 2013).
Taken together, it seems that brexpiprazole can ameliorate
cognitive deﬁcits associated with NMDA receptor dysfunction,
via its 5-HT1A agonistic activity. Further studies are needed to
clarify the effects of other antipsychotic drugs with 5-HT1A
agonistic activity, on social cognition in patients.
Previous reports demonstrated that 5-HT1A receptor antago-
nists impair sociability in rodents, and that 5-HT1A receptor
agonists improved sociability in the social interaction in rodents
(File and Seth, 2003; Bruins Slot et al., 2005; Snigdha and Neill,
2008; Gould et al., 2011). These ﬁndings suggest an important
role of 5-HT1A receptors in social behaviors. A recent study
showed that the rewarding properties of social interaction in
mice require the coordinated activity of oxytocin and 5-HT1B
receptor in the nucleus accumbens, which are implicated in the
social cognitive dysfunction in patients with a number of
psychiatric diseases (Dolen et al., 2013). Since brexpiprazole
has a moderate afﬁnity at 5-HT1B receptor (Ki=32 nM) (Maeda
et al., 2014a), it is possible that 5-HT1B receptor may, in part,
be involved in the mechanisms of action of brexpiprazole on
social recognition deﬁcits. Nonetheless, further studies of the
role of 5-HT1B receptors in the mechanisms of action of
brexpiprazole would be needed to conﬁrm this hypothesis.
In conclusion, brexpiprazole ameliorated social recognition
deﬁcits in mice after administration of dizocilpine, and the
5-HT1A receptor antagonist WAY-100,635 reversed the effects of
brexpiprazole in this model. Our results imply that brexpipra-
zole could potentially serve as a therapeutic drug to treat social
cognitive deﬁcits in patients with schizophrenia and MDD.Role of funding source
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